Business Wire

MOODY’S-ESG-SOLUTIONS

Share
Moody’s Launches New Platform to Deliver Comprehensive and Actionable ESG Data and Insights

Moody’s today launched Moody’s ESG360™, an easy-to-use platform that provides portfolio managers with ESG analyst-verified scores and modelled ESG and climate intelligence on private and public companies to bring clarity and confidence to investment decisions on environmental, social and governance (ESG) issues.

“To understand the short- and long-term impact of ESG and climate exposures, market participants need a holistic and reliable view of risks and opportunities,” said Andrea Blackman, Managing Director – Global Head of Moody’s ESG Solutions. “The launch of Moody’s ESG360™ demonstrates our commitment to providing comprehensive coverage to help portfolio managers make sustainable decisions with confidence. Coverage is much more than just a number; it’s a commitment to providing granular and clearly defined data, scores, and assessments – all delivered through platforms that meet customer needs.”

Moody’s ESG360™ allows portfolio managers to identify ESG leaders and laggards across themes, sectors, and regions, monitor and report on portfolio level performance across a broad range of research lines, and analyze key risk metrics at both the portfolio and entity level. All data points will be clearly labeled with their relevance to industry standards and traceable to their source.

At launch, Moody’s ESG360™ provides access to Moody’s physical and transition climate risk data sets across a recently expanded universe of 10,000 companies globally. In the coming months, the platform will be further enhanced with Moody’s ESG insights, including coverage of 300 million public and private companies through a combination of modelled and ESG analyst-verified scores.

Driven by a double materiality approach that accounts for both financial and stakeholder impacts, Moody’s ESG data, scores, and assessments provide a comprehensive view of the ESG performance of companies – including small and medium-sized enterprises (SMEs). This enables a unique assessment of how companies can create sustainable value for the environment, society, and stakeholders, as well as how companies are positioned to manage their exposure and response to ESG risks and opportunities.

Alongside Moody’s ESG360™, Moody’s recently launched a corporate engagement platform, Moody’s ESG360™ Connect, which enables corporates to easily connect with Moody’s regarding their sustainability disclosures and ensure accurate representation of their ESG data, ultimately expanding the data coverage that feeds into Moody’s ESG solutions.

To learn more about Moody’s ESG360™ or get a demo, visit: http://www.moodys.com/moodys-esg360 .

Sustainability is at the core of Moody's business, building better business, better lives and better solutions to create long-term value for society, the environment and the economy. For more information on Moody’s sustainability commitments, visit: https://about.moodys.io/sustainability

ABOUT MOODY’S ESG SOLUTIONS

Moody’s ESG Solutions is a business unit of Moody’s Corporation serving the growing global demand for ESG and climate insights. The group leverages data and expertise across ESG, climate risk, and sustainable finance, and aligns with Moody's Investors Service and Moody's Analytics to deliver a comprehensive, integrated suite of ESG and climate risk solutions including ESG scores, analytics, Sustainability Ratings and Sustainable Finance Reviewer/certifier services.

For more information visit, Moody’s ESG hub at www.moodys.com/esg .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release

Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release

Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye